UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	6 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Cash flows from operating activities
Net income	$ 37,167	$ 10,864
Adjustments to reconcile net income to net cash used in operating activities:
Depreciation and amortization expense	41,438	34,376
Stock-based compensation expense	17,967	11,699
Deferred income taxes	5,375	346
Provision for (recovery of) doubtful accounts	6,382	(344)
Amortization of discount and fees on debt	4,973
Other	16,871	7,116
Changes in assets and liabilities:
Accounts receivable	(208,870)	(59,650)
Inventories, prepaid expenses, deposits and other current and long-term assets	(23,231)	2,556
Accounts payable	(7,202)	(14,141)
Accrued liabilities	4,346	690
Accrued compensation and benefits	(5,401)	(13,943)
Operating lease liability	(10,364)	(4,089)
Deferred revenue and other liabilities	40,592	3,255
Net cash used in operating activities	(79,957)	(21,265)
Cash flows from investing activities
Purchase of property and equipment	(1,969)	(1,338)
Capitalized software development costs	(14,061)	(12,978)
Capitalized curriculum development costs	(7,524)	(11,991)
Sale of long-lived assets	223
Acquisition of MedCerts, LLC, net of cash acquired	(54,775)
Acquisition of Tech Elevator, Inc., net of cash acquired	(15,981)
Other acquisitions and investments, net of distributions	(188)	(4,114)
Net cash used in investing activities	(94,275)	(30,421)
Cash flows from financing activities
Repayments on finance lease obligations	(11,455)	(14,959)
Repayments on credit facility	(100,000)
Issuance of convertible senior notes	408,610
Purchases of capped calls in connection with convertible senior notes	(60,354)
Proceeds from exercise of stock options	303	48
Withholding of stock options for tax withholding	(10,885)
Repurchase of restricted stock for income tax withholding	(6,108)	(4,883)
Net cash provided by (used in) financing activities	220,111	(19,794)
Net change in cash, cash equivalents and restricted cash	45,879	(71,480)
Cash, cash equivalents and restricted cash, beginning of period	213,299
Cash, cash equivalents and restricted cash, end of period	$ 259,178	$ 213,141